Acepodia Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 48

Employees

  • Stock Symbol
  • 6976

Stock Symbol

  • Share Price
  • $0.53
  • (As of Thursday Closing)

Acepodia General Information

Description

Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Contact Information

Website
www.acepodia.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1600 Harbor Bay Parkway
  • Suite 140
  • Alameda, CA 94502
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
ROCO
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1600 Harbor Bay Parkway
  • Suite 140
  • Alameda, CA 94502
  • United States
+1 (415)

Acepodia Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Acepodia Stock Performance

As of 10-Jul-2025, Acepodia’s stock price is $0.53. Its current market cap is $305M with 574M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.53 $0.54 $0.42 - $0.83 $305M 574M 320K -$0.03

Acepodia Financials Summary

As of 31-Dec-2024, Acepodia has a trailing 12-month revenue of $13.3K.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 117,458 117,458 426,945
Revenue 13 13 533 0
EBITDA (20,601) (20,601) (28,790) (47,543)
Net Income (15,480) (15,480) (26,240) (47,508)
Total Assets 207,375 207,375 221,899 126,233
Total Debt 9,473 9,473 8,911 1,708
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Acepodia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Acepodia‘s full profile, request access.

Request a free trial

Acepodia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cel
Drug Discovery
Alameda, CA
48 As of 2023

South San Francisco, CA
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Acepodia Competitors (48)

One of Acepodia’s 48 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
ArsenalBio Venture Capital-Backed South San Francisco, CA
Jasper Therapeutics Formerly VC-backed Redwood City, CA
You’re viewing 5 of 48 competitors. Get the full list »

Acepodia Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Acepodia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4448730-A1 A novel method of treating targeted abnormal cells, and cytotoxic cell used therein Pending 13-Dec-2021
EP-4322972-A1 Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof Pending 16-Apr-2021
EP-4322972-A4 Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof Pending 16-Apr-2021
EP-3911340-A1 A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell Pending 18-Jan-2019
EP-3911340-A4 A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell Pending 18-Jan-2019 C12N5/0636
To view Acepodia’s complete patent history, request access »

Acepodia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Acepodia FAQs

  • When was Acepodia founded?

    Acepodia was founded in 2014.

  • Where is Acepodia headquartered?

    Acepodia is headquartered in Alameda, CA.

  • What is the size of Acepodia?

    Acepodia has 48 total employees.

  • What industry is Acepodia in?

    Acepodia’s primary industry is Drug Discovery.

  • Is Acepodia a private or public company?

    Acepodia is a Public company.

  • What is Acepodia’s stock symbol?

    The ticker symbol for Acepodia is 6976.

  • What is the current stock price of Acepodia?

    As of 10-Jul-2025 the stock price of Acepodia is $0.53.

  • What is the current market cap of Acepodia?

    The current market capitalization of Acepodia is $305M.

  • What is Acepodia’s current revenue?

    The trailing twelve month revenue for Acepodia is $13.3K.

  • Who are Acepodia’s competitors?

    CytomX Therapeutics, Inovio Pharmaceuticals, Sorrento Therapeutics, ArsenalBio, and Jasper Therapeutics are some of the 48 competitors of Acepodia.

  • What is Acepodia’s annual earnings per share (EPS)?

    Acepodia’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »